Introduction
Cholesterol is present in tissues and plasma lipoproteins either as free cholesterol (FC) or cholesteryl esters (CE). The esterification of cholesterol in plasma by lecithin: cholesterol acyltransferase (LCAT) plays an important role in the intravascular maturation of lipoproteins, especially high density lipoproteins (HDL). In contrast, intracellular CE synthesis, catalyzed by acyl-CoA:cholesterol acyltransferase (ACAT), serves to store cholesterol in cytosolic droplets and also participates in the hepatic secretion of lipoproteins containing apoB (1) (2) (3) . Moreover, ACAT is believed to be involved in cholesterol absorption from the intestines (4) .
Two ACAT isoforms (ACAT-1 and ACAT-2) have been reported in humans, nonhuman primates and mice (5) (6) (7) . ACAT-1 is ubiquitously expressed in the tissues of all the animals examined (6, (8) (9) (10) . In contrast, ACAT-2 is expressed mainly in the liver and intestine in mice and nonhuman primates (5, 6) , but only in the intestine in humans (11) . Recently, Kusunoki and co-workers reported that postprandial hyperlipidemia in diabetic rats was caused by an increase in intestinal ACAT activity (12) . The data suggest that ACAT-2 may play an important role in the metabolism of triglyceride-rich lipoproteins. We hypothesized that ACAT-2 may be the principal enzyme responsible for cholesterol esterification and chylomicron assembly in the small intestine, and sought to determine the role of cholesterol ester synthesis in processes such as cholesterol absorption and lipoprotein as-sembly in humans. To investigate these questions, we examined the relationship between ACAT-2 gene mutations and dyslipidemia. Our previous study revealed that three single-nucleotide polymorphisms (SNPs) in the ACAT-2 gene (E14G, T254I and IVS7) were not closely associated with plasma concentrations of lipids (13) . In this study, we identified another SNP (IVS1 -8G→C) in the ACAT-2 gene and examined the relationship between this SNP and plasma concentrations of lipids or apolipoproteins.
Materials and Methods

Subjects
Outpatients at the Department of Pediatrics, University of the Ryukyus and the Department of Internal Medicine, Hiroshima Hospital of West-Japan Railway Company, who had visited the respective hospitals for a routine checkup for dyslipidemia, were screened for ACAT-2 mutations. Normolipidemic subjects consisted of students and volunteers from the staff of the Faculty of Medicine, University of the Ryukyus. The design and method of this study were approved by the Ethics Committee of the Faculty of Medicine, University of the Ryukyus. Venous blood was drawn after an overnight fast. Informed consent was obtained from all of the subjects or their parents.
DNA analysis
Genomic DNA was purified from white blood cells, and in vitro amplification of genomic DNA was performed by PCR. Multiple pairs of primers were synthesized to amplify each of the ACAT-2 exonic regions with intronic borders (13) . PCR consisted of 35 cycles of denaturation at 94 °C for 30 sec, annealing at 55-60 °C for 30 sec and extension at 72 °C for 1 min in 50 µl of reaction mixture containing 1.5 mM MgCl2, 300 µM of each dNTP (Nippon Gene, Japan), 0.3 µM of each primer, and 2.5 U of Taq DNA polymerase (Nippon Gene, Japan). Finally, PCR products were purified with the QIA quick Gel Extraction Kit (Qiagen KK, Japan). The abundance and quality of DNA fragments were analyzed by electrophoresis on 1.2% agarose gel, followed by ethidium bromide staining and inspection under UV light. Direct sequencing of doublestrand DNA fragments of exons 1 through 15 was performed using the internal sequencing primers (13) .
Analysis of lipids and apolipoproteins
Plasma levels of total TC, TG and HDL-C were analyzed using an autoanalyzer and enzymatic methods, or by selective precipitation using sodium phosphotungstate and magnesium chloride (14, 15) . LDL-C was calculated as TC -(HDL-C + TG/5). Apolipoproteins were measured by the turbidity immunoassay method (16) .
Statistical evaluation
One-way ANOVA and the chi-square test were used to evaluate the data. Differences between groups with p < 0.05 were considered statistically significant.
Results
Screening for ACAT-2 gene mutations
In this study, to identify other SNPs, we screened 30 subjects with hyperlipidemia [15 males and 15 females, 49 ± 7 years old (mean ± SD), all native Japanese] [ TC > 220 mg/dl (5.69 mmol/l) or TG > 150 mg/dl (1.69 mmol/l)]. First, to amplify the exonic regions and the splice junction sites, PCR primers were chosen in intronic regions -25 to -100 bp from the intron-exon boundaries (13) . The resulting PCR products were then analyzed by direct sequencing. As a result, one new SNP was detected in an intervening sequence 1 (IVS1 -8 G→C; IVS1) ( Table 1) . To estimate the prevalence of IVS1, 91 unrelated hyperlipidemic subjects [40 males and 51 females, 45 ± 11 years old (mean ± SD), all native Japanese] [TC > 220 mg/dl (5.69 mmol/l) or TG > 150 mg/dl (1.69 mmol/l)], and 92 unrelated normolipidemic subjects [46 males and 46 females, 35 ± 12 years old (mean ± SD), all native Japanese] [TC < 220 mg/dl (5.69 mmol/l) and TG < 150 mg/dl (1.69 mmol/l)] were screened by direct sequencing of the second exonic region and the splice junction site. Next, the relationships between this SNP and both plasma lipids and apolipoproteins were determined. All data regarding plasma lipids and apolipoproteins in hyperlipidemic subjects were obtained before prescribing lipidlowering drugs. None of the normolipidemic subjects was taking drugs that affected lipid metabolism. As shown in Tables 2 and 3 , only one and two of the normolipidemic and hyperlipidemic subjects, respectively, were homozygous, while 23 % of the normolipidemic subjects and 22 % of the hyperlipidemic subjects were heterozygous for IVS1 SNP. The incidences of homozygotes, heterozygotes and subjects without mutation among normolipidemic subjects were similar to those in hyperlipidemic subjects. The frequencies of the IVS1 allele in normolipidemic and hyperlipidemic subjects were 0.131 and 0.125, respectively. The frequencies of this SNP allele in hyperlipidemic subjects were similar to those in normolipidemic subjects. The IVS1 SNP did not affect plasma concentrations of lipids or apolipoproteins in either normolipidemic or hyperlipidemic subjects (Tables 2 and 3 ). To determine the Lower-case letters indicate intronic sequence. effects of IVS1 SNP on different types of hyperlipidemia, we classified hyperlipidemia into Type IIa, IIb, and IV (criteria for hyperlipidemic subjects, IIb: TC > 220 mg/dl and TG > 150 mg/dl, IIa: TC > 220 mg/dl and TG < 150 mg/dl, IV: TC< 220 mg/dl and TG> 150 mg/dl). No significant differences were found in plasma concentrations of other lipids and apolipoproteins (data not shown).
Discussion
The enzyme involved in intracellular cholesterol esterification, ACAT, was isolated after a long search (8) . This led to the identification of the ACAT isoforms ACAT-1 and ACAT-2. ACAT-1 is ubiquitously expressed in the tissues of all the animals examined (6, (8) (9) (10) . In contrast, animal studies using mice and nonhuman primates have shown that ACAT-2 is expressed mainly in the liver and intestine, with only minor amounts in other tissues. ACAT-2 message was detected in human liver-derived HepG2 cells and intestinally derived CaCo2 cells by RT-PCR (11). Thus, until recently, it was believed that, as in nonhuman primates and mice, ACAT-2 might be expressed in both the liver and intestine in humans. Buhman and co-workers observed that ACAT-2-deficient mice have a reduced capacity to absorb cholesterol and are resistant to dietinduced hypercholesterolemia, and showed that ACAT-2 plays a major regulatory role in the response of plasma cholesterol levels to dietary cholesterol (18) . Therefore, it seems reasonable to consider whether abnormalities within the ACAT-2 gene are related to dyslipidemia in humans. We thought that ACAT-2 is the major enzyme responsible for cholesterol esterification in the small intestine, and sought to determine the role of cholesterol ester synthesis in processes such as cholesterol absorption and chylomicrons assembly in humans. To determine the roles of human ACAT-2 gene, we investigated the relationship between ACAT-2 gene mutation and dyslipidemia. In this study, we searched for abnormalities or polymorphisms within the ACAT-2 gene. As a result, a new SNP (IVS1) was found in hyperlipidemic and normolipidemic subjects. The frequency of this SNP in hyperlipidemic subjects was similar to that in normolipidemic subjects, and this SNP was not related to plasma levels of lipids and apolipoproteins in hyperlipidemic or normolipidemic subjects. In a previous study, we identified three other SNPs. However, these three SNPs were also not closely associated with plasma concentrations of lipids.
The physiological roles of ACAT-1 and ACAT-2 in humans are currently under intensive investigation by several laboratories, but remain unclear. Rudel and co-workers recently identified ACAT-2 in the rough endoplasmic reticulum of essentially all hepatocytes in monkeys and suggested that ACAT-2 is the primary form of ACAT in the human liver (19) . On the other hand, Chang and co-workers suggested that the primary ACAT in the human liver is ACAT-1, while ACAT-2 is the primary ACAT in the human intestine (20) , and immunohistochemical studies by Sakashita and co-workers have suggested that ACAT-1 is the major ACAT isoform in the adult human liver, while ACAT-2 is the major isoform in the intestine (11, 21) . Our previous and present findings that four SNPs in the ACAT-2 gene are not closely associated with plasma concentrations of lipids or apolipoproteins may support these immunohistochemical data. Although further studies are needed, our data suggest that the ACAT-2 gene may not affect lipid levels in humans.
